NEUROONE MEDICAL TECHNOLOGIES Corp NMTC
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
-19.57
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.1M | -$3.6M | $5.1M | -$2.9M | $7.1M |
| 2024 | $3.5M | -$12.3M | $1.1M | -$11.1M | $822,013 |
| 2023 | $2.0M | -$11.9M | $456,517 | -$13.3M | $6.2M |
| 2022 | $171,169 | -$10.0M | -$70,794 | -$7.8M | $9.6M |
| 2021 | $178,146 | -$9.9M | -$97,749 | -$8.7M | $6.6M |
| 2020 | — | -$13.6M | — | -$3.5M | $2.1M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.57 (distress)
- Working capital / assets 0.735
- Retained earnings / assets -7.288
- EBIT / assets -0.392
- Equity / liabilities 1.905
Source: SEC EDGAR filings · CIK 0001500198 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.